These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 30211110)

  • 1. Cell-Free DNA Profiling to Discover Mechanisms of Exceptional Response to Cabozantinib Plus Panitumumab in a Patient With Treatment Refractory Metastatic Colorectal Cancer.
    Jia J; Morse MA; Nagy RJ; Lanman RB; Strickler JH
    Front Oncol; 2018; 8():305. PubMed ID: 30211110
    [No Abstract]   [Full Text] [Related]  

  • 2. Cabozantinib and Panitumumab for RAS Wild-Type Metastatic Colorectal Cancer.
    Strickler JH; Rushing CN; Uronis HE; Morse MA; Niedzwiecki D; Blobe GC; Moyer AN; Bolch E; Webb R; Haley S; Hatch AJ; Altomare IP; Sherrill GB; Chang DZ; Wells JL; Hsu SD; Jia J; Zafar SY; Nixon AB; Hurwitz HI
    Oncologist; 2021 Jun; 26(6):465-e917. PubMed ID: 33469991
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cabozantinib with or without Panitumumab for RAS wild-type metastatic colorectal cancer: impact of MET amplification on clinical outcomes and circulating biomarkers.
    Jia J; Howard L; Liu Y; Starr MD; Brady JC; Niedzwiecki D; Strickler JH; Nixon AB
    Cancer Chemother Pharmacol; 2022 Mar; 89(3):413-422. PubMed ID: 35171350
    [TBL] [Abstract][Full Text] [Related]  

  • 4. KRAS Testing for Anti-EGFR Therapy in Advanced Colorectal Cancer: An Evidence-Based and Economic Analysis.
    Medical Advisory Secretariat
    Ont Health Technol Assess Ser; 2010; 10(25):1-49. PubMed ID: 23074403
    [TBL] [Abstract][Full Text] [Related]  

  • 5. REMARRY and PURSUIT trials: liquid biopsy-guided rechallenge with anti-epidermal growth factor receptor (EGFR) therapy with panitumumab plus irinotecan for patients with plasma RAS wild-type metastatic colorectal cancer.
    Nakajima H; Kotani D; Bando H; Kato T; Oki E; Shinozaki E; Sunakawa Y; Yamazaki K; Yuki S; Nakamura Y; Yamanaka T; Yoshino T; Ohta T; Taniguchi H; Kagawa Y
    BMC Cancer; 2021 Jun; 21(1):674. PubMed ID: 34098908
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The clinical effectiveness and cost-effectiveness of cetuximab (mono- or combination chemotherapy), bevacizumab (combination with non-oxaliplatin chemotherapy) and panitumumab (monotherapy) for the treatment of metastatic colorectal cancer after first-line chemotherapy (review of technology appraisal No.150 and part review of technology appraisal No. 118): a systematic review and economic model.
    Hoyle M; Crathorne L; Peters J; Jones-Hughes T; Cooper C; Napier M; Tappenden P; Hyde C
    Health Technol Assess; 2013 Apr; 17(14):1-237. PubMed ID: 23547747
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recommendations from the EGAPP Working Group: can testing of tumor tissue for mutations in EGFR pathway downstream effector genes in patients with metastatic colorectal cancer improve health outcomes by guiding decisions regarding anti-EGFR therapy?
    Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Working Group
    Genet Med; 2013 Jul; 15(7):517-27. PubMed ID: 23429431
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Spotlight on panitumumab in metastatic colorectal cancer.
    Keating GM
    BioDrugs; 2010 Aug; 24(4):275-8. PubMed ID: 20623992
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis.
    De Roock W; Claes B; Bernasconi D; De Schutter J; Biesmans B; Fountzilas G; Kalogeras KT; Kotoula V; Papamichael D; Laurent-Puig P; Penault-Llorca F; Rougier P; Vincenzi B; Santini D; Tonini G; Cappuzzo F; Frattini M; Molinari F; Saletti P; De Dosso S; Martini M; Bardelli A; Siena S; Sartore-Bianchi A; Tabernero J; Macarulla T; Di Fiore F; Gangloff AO; Ciardiello F; Pfeiffer P; Qvortrup C; Hansen TP; Van Cutsem E; Piessevaux H; Lambrechts D; Delorenzi M; Tejpar S
    Lancet Oncol; 2010 Aug; 11(8):753-62. PubMed ID: 20619739
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase II Trial of Trametinib and Panitumumab in RAS/RAF Wild Type Metastatic Colorectal Cancer.
    Alshammari K; Aung KL; Zhang T; Razak ARA; Serra S; Stockley T; Wang L; Nguyen J; Spreafico A; Hansen AR; Zwir D; Siu LL; Bedard PL
    Clin Colorectal Cancer; 2021 Dec; 20(4):334-341. PubMed ID: 34417144
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase II Study of Tivantinib and Cetuximab in Patients With KRAS Wild-type Metastatic Colorectal Cancer With Acquired Resistance to EGFR Inhibitors and Emergence of MET Overexpression: Lesson Learned for Future Trials With EGFR/MET Dual Inhibition.
    Rimassa L; Bozzarelli S; Pietrantonio F; Cordio S; Lonardi S; Toppo L; Zaniboni A; Bordonaro R; Di Bartolomeo M; Tomasello G; Dadduzio V; Tronconi MC; Piombo C; Giordano L; Gloghini A; Di Tommaso L; Santoro A
    Clin Colorectal Cancer; 2019 Jun; 18(2):125-132.e2. PubMed ID: 30846365
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Panitumumab: a review of its use in metastatic colorectal cancer.
    Keating GM
    Drugs; 2010 May; 70(8):1059-78. PubMed ID: 20481659
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neratinib-Plus-Cetuximab in Quadruple-WT (
    Jacobs SA; Lee JJ; George TJ; Wade JL; Stella PJ; Wang D; Sama AR; Piette F; Pogue-Geile KL; Kim RS; Gavin PG; Lipchik C; Feng H; Wang Y; Finnigan M; Kiesel BF; Beumer JH; Wolmark N; Lucas PC; Allegra CJ; Srinivasan A
    Clin Cancer Res; 2021 Mar; 27(6):1612-1622. PubMed ID: 33203645
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Panitumumab in patients with KRAS wild-type colorectal cancer after progression on cetuximab.
    Wadlow RC; Hezel AF; Abrams TA; Blaszkowsky LS; Fuchs CS; Kulke MH; Kwak EL; Meyerhardt JA; Ryan DP; Szymonifka J; Wolpin BM; Zhu AX; Clark JW
    Oncologist; 2012; 17(1):14. PubMed ID: 22210091
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer.
    Di Nicolantonio F; Martini M; Molinari F; Sartore-Bianchi A; Arena S; Saletti P; De Dosso S; Mazzucchelli L; Frattini M; Siena S; Bardelli A
    J Clin Oncol; 2008 Dec; 26(35):5705-12. PubMed ID: 19001320
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rationale for and Design of the PARADIGM Study: Randomized Phase III Study of mFOLFOX6 Plus Bevacizumab or Panitumumab in Chemotherapy-naïve Patients With RAS (KRAS/NRAS) Wild-type, Metastatic Colorectal Cancer.
    Yoshino T; Uetake H; Tsuchihara K; Shitara K; Yamazaki K; Oki E; Sato T; Naitoh T; Komatsu Y; Kato T; Yamanaka K; Iwasaki K; Soeda J; Hihara M; Yamanaka T; Ochiai A; Muro K
    Clin Colorectal Cancer; 2017 Jun; 16(2):158-163. PubMed ID: 28237539
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Circulating tumor DNA to guide rechallenge with panitumumab in metastatic colorectal cancer: the phase 2 CHRONOS trial.
    Sartore-Bianchi A; Pietrantonio F; Lonardi S; Mussolin B; Rua F; Crisafulli G; Bartolini A; Fenocchio E; Amatu A; Manca P; Bergamo F; Tosi F; Mauri G; Ambrosini M; Daniel F; Torri V; Vanzulli A; Regge D; Cappello G; Marchiò C; Berrino E; Sapino A; Marsoni S; Siena S; Bardelli A
    Nat Med; 2022 Aug; 28(8):1612-1618. PubMed ID: 35915157
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biomarkers predicting clinical outcome of epidermal growth factor receptor-targeted therapy in metastatic colorectal cancer.
    Siena S; Sartore-Bianchi A; Di Nicolantonio F; Balfour J; Bardelli A
    J Natl Cancer Inst; 2009 Oct; 101(19):1308-24. PubMed ID: 19738166
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Panitumumab and irinotecan versus irinotecan alone for patients with KRAS wild-type, fluorouracil-resistant advanced colorectal cancer (PICCOLO): a prospectively stratified randomised trial.
    Seymour MT; Brown SR; Middleton G; Maughan T; Richman S; Gwyther S; Lowe C; Seligmann JF; Wadsley J; Maisey N; Chau I; Hill M; Dawson L; Falk S; O'Callaghan A; Benstead K; Chambers P; Oliver A; Marshall H; Napp V; Quirke P
    Lancet Oncol; 2013 Jul; 14(8):749-59. PubMed ID: 23725851
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase II and Biomarker Study of Cabozantinib in Metastatic Triple-Negative Breast Cancer Patients.
    Tolaney SM; Ziehr DR; Guo H; Ng MR; Barry WT; Higgins MJ; Isakoff SJ; Brock JE; Ivanova EV; Paweletz CP; Demeo MK; Ramaiya NH; Overmoyer BA; Jain RK; Winer EP; Duda DG
    Oncologist; 2017 Jan; 22(1):25-32. PubMed ID: 27789775
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.